by DrKSSMDPhD | January 9, 2015 3:31 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2015/01/the-2015-stock-gumshoe-biotechnology-awards-show/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
“Publicly-Traded Biotech We Most Want to See Listed in the US in 2015
Molecular Partners (Switzerland)”
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
DrKSS, I copied this from the above story and found that I can purchase some shares for my Fidelity account as MOLN:CH. Today it closed at CHF 23.0, i.e., 23.0 Swiss Franks that would cost $25.40 at today’s dollar exchange rate; it was down 5.09% today , and down from a peak of around CHF 26.5 a couple weeks ago, or roughly 15%. It “develops targeted protein … DARPins…” Until it gets a U.S. listing do you suppose the stock performance will likely be a laggard?
.
HTG MOLECULAR DIAGNOSTICS, INC., filed for NASDAQ listing as HTGM on 12/30/14.
Form S1 Registration Statement at http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=9923843
Board of Directors at http://www.molecularpartners.com/aboutus/board-of-directors/
Just so we’re clear: HTG Molecular Diagnostics and Molecular Partners are NOT the same company based on research. I assume you included them here Hi Pockets as they’re in the same space or just because they’re IPOing or … ?
Allison – As a Texas Governor famously said: “OOPS”. I searched NASDAQ for “Molecular Partners” and thought I had found it when I saw the link to Molecular Diagnostics. Thanks for the catch.- I should have read the link a tad better.
As long as we’re here, from the HTG Molecular Diagnostics web site http://www.htgmolecular.com/why-htg/why-htg : “Tumor profiling, which combines test results from techniques such as immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR) and next-generation sequencing (NGS), is becoming increasingly available to oncologists. The proliferation of these technologies, while exciting, presents several challenges to widespread adoption in the clinic. HTG Molecular Diagnostics, Inc. is focused on delivering on the promise of these tumor profiling breakthroughs through reduced usage of precious tissue specimens, platform consolidation, and optimization of testing efficiency. “
Not our cup of tea. Shucks! 🙂
Diphenhydramine is the generic form of the antihistamine Benadryl and that is the ingredient which makes you sleep and which Dr. KSS warned against. Youngsters overdo antihistamine to get a mild delirium high. It dulls cognitive thinking and not good for young or old on a continuous basis. Trazodone is an excellent choice if it works. A rare side effect (in males) is priapism, a painful sustained erection which requires immediate treatment to prevent the loss of erectile function.
Thanks, I have some 100mg Trazodone tablets that I cut in half, so I take 50mg for a dose. That seems to work but my side effects are a bit of nasal stuffiness and a bit of a bad taste in my mouth the next day. Plus I don’t yet have an Rx for it, so it costs me $$. I’ve been using the generic form of ZzzQuil, instead. I guess I’ll get an Rx for it next Dr visit in a couple of months, and pay for it until then.
Doctor,
I’m also a long-time Diphenhydramine HCL (Unisom) user for sleep. Could you please tell me what dosage of Trazodone you take? I’m looking forward to trying it.
Thanks!
I don’t take trazodone as I am one of the lucky ones who can sleep well. Dr. KSS mentioned he takes it. Don’t know his dose. People usually start at 50-100mg, which is usually sufficient but go higher if needed. Please know that trazodone is FDA approved for depression, but much higher doses are needed, so using it for insomnia, which is common, is considered off label, meaning no FDA approval, but in this case that is no big deal.
Trazodone article:
http://www.consumerreports.org/cro/2012/04/trazodone-common-sleep-drug-is-little-known-antidepressant/index.htm
Thank you, Dan. This info will help me.
IIRC, Doc Gumshoe did a piece on sleep aids. Anyone interested should search the archives for it.
Scorpio,
I’m a bit confused in how you are taking Trazodone without a prescription, or maybe I misunderstood your post.
Yes, taking without a prescription. The good doctors may frown on me, but there are ways to get drugs (legal to buy without Rx in some countries like the UK) from overseas. Many of the places are probably selling fake drugs, so I would be very careful.
And for the record, I should probably say I am lying, and that I don’t take non-Rx’d medication.
$NBY
I just saw a patient with chronic posterior blepharitis (gooey eyelids that predispose to styes) due to polypharmacy. She is on multiple meds for seizures, depression, allergies, hypertension. She’s a smart woman who complains that her memory and energy level is geting worse (ie she is approaching a KSS level 5/10 brain-drug interaction). I had seen her 1 month ago and iLid Cleanser had totally alleviated her symptoms, but she ran out of it and forgot this symptomatic triumph until I asked about it. Nothing else works. I just told the Bausch and Lomb rep about Novabay when she asked why I wasn’t prescribing her steroid drops as much. She’s never heard about it (future Valeant buyout)?
Well, the patient is happy about being back on iLid Cleanser and I am about to call her Internist to suggest a trial of less meds.
Eyedoc,
NBY. Thanks for the informative update. I have yet to find any negative information on iLid Cleanser. Long NBY.
V/R
Tom
$AAVL, $OPHT, $ACT, $RHHBY
In the future, if its AAV gene therapy works, AAVL investors will predictably realize substantial profits. However, I don’t believe that AAVL’s current anti-VEGF therapy will ultimately prove sufficient in and by itself to fully treat AMD.
I believe SOC will require both an anti VEGF and an anti PDGF, like $OPHT’s Fovista. OPHTs clinical trials are really coming along and I believe they will show good data. A positive showing for phase 3 OPHT will be a lightening strike in AMD therapy. I suggest that gummies read the company website and see if it excites you. OPHT may also be a little less risky then AAVL, which is really a first in man gene therapy trial like CLDN. You might want to buy a few shares of OPHT if you can understand it. AMD therapy is going to be a world full of joint anti-VEGF and anti PDGF therapies. This is why OPHT is in two phase 3 trials l combining Fovista with Lucentis or Eylea.
$ACT just bought Allergan. Allergan licensed DARPin technology from the Swiss company Molecular Partners. The DARPins are small proteins that can bind together antiVEGF and antiPDGF molecules into one molecule. This should combine two intravitreal injections into one, a huge plus. In addition, the injections are said to be able to last for many months instead of just one month. This is breathtaking. You can invest in this via ACT shares. Go to the Allergan website and look at its pipeline to see this. There are two DARPin drugs for AMD. The one in phase 2 will compete with (and may trample) AAVL, Roche (Avastin amd Lucentis) and REGN (Eylea). The second one is still preclinica land is the big one. I believe they are awaiting the results of OPHTs Fovista trial to decide if they are going to press on. At that point, $ACT will purchase $OPHT……..I think……..or they may be more aggressive and develop an anti PDGF molecule of their own (very slow, expensive and risky). If a purchase occurs, it will be one of the most expensive purchases in history.
AAVL, if successful, would need to give Fovista injections on the side or launch another project to make genes for both circulating flt receptors to bind VEGF as well as
something to stimulate anti PDGF effects . Again, a long, expensive and risky project.
I have invested in all three as in a basket, but am very weighted towards ACT, since it is a much less risky investment. I would weight yourself more towards OPHT
than AAVL, although both are good companies. We already have anti VEGF treatments, the future is in anti PDGF. The potential for these dwarf the potential for CAR-T, at least in the short term. There is a lot more AMD in the world and CAR-T is a much more difficult and expensive to administer.
If it doesn’t work, I/you will lose in OPHT or AAVL although they could still be bought out for their IP (Alan). $ACT will do well long term. I am not putting a lot of money on either OPHT or AAVL (100 shares each). I am really excited about the potential near to mid term 1-2 year returns on the basket.
Long $AAVL, $OPHT, $ACT
Thanks to Larry McKenna for editing the first sentence.
Sorry, Larry actually edited a lot more than that ! (-:
For eyedoc: We are most grateful to you for taking the time to share your specialized expertise pertaining to the diagnosis and treatment of eye disease.
Esperion Therapeutics Shares Rise ~18% Premarket on Credit Suisse Comments that Co is Likely Acquisition Target, Raises PT to $100 from $41
8:46a ET February 3, 2015 (Benzinga)
Yes, and Irregulars have known this for months. One of the main points in my column on $ESPR was that it will be taken over…probably by $PFE but if not by them, then one of many Big Cool Friends.
Thanks for the original ESPR article. Today I hit 202% gain on my first position.
Saturday 3/14/15/ at exactly 09:26:53 GMT tou can celebrate PI day/second to the sixth place’ Cheers.
A friend in Chicago is pouring a double g and t for himself at 9:26 am and 9:26 pm.
You can join this young chap at New Jersey for a pie, not old enough for g and t yet.
http://www.edhat.com/daypics2011/Pi-Day-Princeton-Einstein-Look-A-Like-Contest.jpg